1. Self-assembled mRNA vaccines
- Author
-
Yulia Eygeris, Gaurav Sahay, Mohit Gupta, and Jeonghwan Kim
- Subjects
HPLC, High-performance liquid chromatography ,TH1, Type 1 T helper cell ,DMG-PEG-2000, 1,2-Dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 ,IV, Intravenous ,Genetic enhancement ,APC, Antigen-presenting cell ,Pharmaceutical Science ,PET-CT, Positron emission tomography- computed tomography ,02 engineering and technology ,LNP, Lipid nanoparticle ,UTR, Untranslated region ,IL, Ionizable lipid ,PEG, Poly(ethylene glycol) ,SARS-CoV-2, Severe acute respiratory syndrome coronavirus-2 ,ID, Intradermal ,ARCA, “Anti-reverse" cap analog ,Nanotechnology ,IM, Intramuscular ,Gene delivery ,GMP, Good manufacturing practice ,IVT, In vitro transcription ,Vaccines, Synthetic ,0303 health sciences ,SAXS, Small-angle X-ray scattering ,Gene Transfer Techniques ,Self-assembly ,PBAE, Poly(beta-amino esters) ,021001 nanoscience & nanotechnology ,DC, Dendritic cell ,mRNA, Messenger RNA ,Vaccination ,DSPC, 1,2-Distearoyl-sn-glycero-3-phosphocholine ,HIV, Human immunodeficiency virus ,COVID-19, Coronavirus Disease 2019 ,siRNA, Small interfering RNA ,DOTAP, 1,2-Dioleoyl-3-trimethylammonium-propane ,RSV, Respiratory syncytial virus ,ApoE, Apolipoprotein E ,0210 nano-technology ,EUA, Emergency Use Authorization ,DOTMA, 1,2-Di-O-octadecenyl-3-trimethylammonium propane ,TLR, Toll-like receptor ,Immune activation ,DODMA, 1,2-Dioleyloxy-3-dimethylaminopropane ,COVID-19 Vaccines ,Coronavirus disease 2019 (COVID-19) ,GC, Germinal center ,Computational biology ,BCR, B-cell receptor ,Biology ,DLin-MC3-DMA, MC3, (6Z,9Z,28Z,31Z)-Heptatriacont-6,9,28,31-tetraene-19-yl 4-(dimethylamino)butanoate ,Article ,Self assembled ,saRNA, Self-amplifying RNA ,03 medical and health sciences ,PEI, Poly(ethylene imine) ,DOPE, 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine ,SAR, Structure-activity relationship ,mRNA delivery ,ACE2, Angiotensin-converting enzyme 2 ,DGTS, 1,2-Dipalmitoyl-sn-glycero-3-O-4'-(N,N,N-trimethyl)-homoserine ,Animals ,Humans ,RNA, Messenger ,IgA, IgG, Immunoglobulin A, G ,030304 developmental biology ,MHC, Major histocompatibility complex ,Messenger RNA ,PLGA, Poly(lactic-co-glycolic acid) ,SC, Subcutaneous ,COVID-19 ,LN, Lymph node ,RBD, Receptor Binding Domain ,Immunization ,Drug Design ,DOGS, N1,N1'-(8-(dioctadecylamino)-5,8-dioxooctane-1,4-diyl)bis(propane-1,3-diaminium) ,Lipid nanoparticles ,Nanoparticles ,pDNA, Plasmid DNA ,Cryo-(T)EM, Cryogenic (transmission) electron microscopy - Abstract
mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology, and nanotechnology have generated interest in delivering safe and effective mRNA therapeutics. In this review, we discuss design and self-assembly of mRNA vaccines. Self-assembly, a spontaneous organization of individual molecules, allows for design of nanoparticles with customizable properties. We highlight the materials commonly utilized to deliver mRNA, their physicochemical characteristics, and other relevant considerations, such as mRNA optimization, routes of administration, cellular fate, and immune activation, that are important for successful mRNA vaccination. We also examine the COVID-19 mRNA vaccines currently in clinical trials. mRNA vaccines are ready for the clinic, showing tremendous promise in the COVID-19 vaccine race, and have pushed the boundaries of gene therapy., Graphical abstract Unlabelled Image, Highlights • mRNA vaccines showed spectacular success in the race for COVID-19 vaccines. • Design of both mRNA and the delivery vectors help in fine-tuning efficacy. • Self-assembled mRNA delivery vectors include lipid and polymer nanoparticles. • Lipid nanoparticle mRNA vaccines have ca. 95% efficacy and earned EUA FDA approval. • These unprecedented results may pave the road for future mRNA vaccine development.
- Published
- 2021
- Full Text
- View/download PDF